; (M) a description of how supported activities are coordinated with— (i) country national TB plans and strategies; and (ii) TB control efforts supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and other international assistance programs and funds, including in the areas of program development and implementation; and (N) for the first 3 years of the report required under this subsection, a description of the progress in recovering from the negative impact of COVID–19 on TB, including— (i) whether there has been the development and implementation of a comprehensive plan to recover TB activities from diversion of resources; (ii) the continued use of bidirectional TB–COVID testing; and (iii) progress on increased diagnosis and treatment of active TB. (j) Annual report on TB research and development The President, acting through the Administrator of the United States Agency for International Development, and in coordination with the National Institutes of Health, the Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority, the Food and Drug Administration, the National Science Foundation, and the Office of the Global AIDS Coordinator, shall submit to the appropriate congressional committees until 2030 an annual report that— (1) describes the current progress and challenges to the development of new tools for the purpose of TB prevention, treatment, and control; (2) identifies critical gaps and emerging priorities for research and development, including for rapid and point-of-care diagnostics, shortened treatments and prevention methods, telehealth solutions for prevention and treatment, and vaccines